dation, impaired development of speech and motor control, and seizures (Ramocki and Zoghbi, 2008) . However, recent work suggests that neurodegeneration may play a role in the pathology of MECP2 DS patients (Reardon et al., 2010) , whereas neurodegeneration has not thus far been associated with RTT. Two recent articles in The Journal of Neuroscience provide insight into MECP2 DS by characterizing animal and cell models of MeCP2 overexpression. Based on results from these studies, we present a hypothesis to link enhanced MeCP2 function to both synaptic deficits and neurodegeneration.
Inthefirststudy,Naetal.(2012)characterized a mouse model of MECP2 DS. Neuronspecific MeCP2 overexpression gave rise to animalswithdecreasedbodyweight,deficitsin motor coordination, increased anxiety-like behavior,andimpairedlearningandmemory, similar to symptoms observed in human MECP2 DS patients. Electrophysiological recordings in hippocampal brain slices from these mice revealed decreases in long-term potentiation (LTP) and the probability of neurotransmitter release, indicative of attenuated synapse strength and activity. Remarkably, administration of a histone deacetylase (HDAC) inhibitor reversed defects in miniature EPSCs observed in cultured hippocampal neurons, suggesting that HDAC-dependent transcriptional repression mediates synaptic defects associated with MeCP2 overexpression. Unexpectedly, the authors found that one previously characterized MeCP2 target gene, brain-derived neurotrophic factor, was not upregulated in their model, suggesting that MeCP2-dependent transcription of other genes must mediate the observed synaptic defects.
In the second article, Dastidar et al. (2012) studied the roles of two previously identified MeCP2 splice variants, MeCP2-e1 and MeCP2-e2, in cultured mouse cerebellar neurons (CCNs). The authors demonstrated that MeCP2-e1 and MeCP2-e2 exhibit different expression profiles and play divergent functional roles in CCNs. When cells were subjected to apoptosis-inducing conditions, mRNA expression of the e2 isoform was upregulated and expression of the e1 isoform was downregulated. Overexpression of MeCP2-e2 promoted apoptosis in healthy cells, whereas MeCP2-e2 knockdown rendered cells resistant to the apoptosis-inducing treatment. In contrast, neither overexpression nor knockdown of MeCP2-e1 affected cell viability. This study further showed that FoxG1, a transcription factor whose dysregulation has also been implicated in RTT, preferentially interacts with MeCP2-e2 and that this interaction restricts the neurotoxic effects of MeCP2-e2. The authors concluded that MeCP2-e2 promotes neuronal cell death when unchecked by FoxG1. This paper provides the first evidence of a functional difference between MeCP2 isoforms, highlighting the necessity of investigating differences between protein isoforms in disease pathogenesis.
It is important to note that the apoptosispromoting isoform of MeCP2, MeCP2-e2, was the one overexpressed in neurons in the Na et al. (2012) Dastidar et al. (2012) explored the role of MeCP2 protein by examining effects of specific isoform overexpression in cerebellar neurons in vitro. In the animal model, the primary nonbehavioral phenotype associated with overexpression was altered synaptic activity in an intact network, and Na et al. (2012) did not explicitly look at cell viability, which was the main defect seen in cultured neurons in Dastidar et al. (2012) .
The relationship between synaptic defects and cell death, the phenotypes found in these two studies, remains unclear because the experiments were conducted in different brain tissues and different preparations. It is possible that MeCP2 function has cell-type and tissue-specific roles, such that its overexpression induces cell death in cerebellum while coordinately altering synaptic function in hippocampus. Synaptic deficits and cell death are also characteristic phenotypes of Alzheimer's disease, and evidence suggests that accumulations of misfolded A␤ oligomers underlie both of these phenotypes (Harmeier et al., 2009) . Protein misfolding and aggregation are not commonly cited characteristics of RTT or MECP2 DS, but recent evidence bridging apoptosis and synaptic activity may provide a different unifying mechanism accounting for the findings of both Dastidar et al. (2012) and Na et al. (2012) . Studies have found that expression of the GluA2 subunit of glutamatergic AMPA receptors (AMPARs) is regulated by the repressor element-1 silencing transcription factor (REST), which is normally maintained at low levels of activity in mature neurons. Increased REST activity in neurons occurs under conditions of cellular stress such as ischemia and epilepsy and leads to silencing of GluA2 expression (Noh et al., 2012) . Decreased levels of GluA2 have been associated with a decrease in LTP (Romberg et al., 2009) , and loss of GluA2 is associated with cell death resulting from excitotoxicity via GluA2-lacking, calcium-permeable AMPARs (Gorter et al., 1997) . Intriguingly, MeCP2 is part of the complex recruited by REST in neurons (Ballas et al., 2005) , and increased expression of MeCP2 has been linked to decreased GluA2 subunit expression and synaptic changes (Qiu et al., 2012) . It is thus tempting to speculate that MeCP2 overexpression acts via REST to affect both synaptic activity and cell death (Fig. 1) .
Analysis of REST activation and GluA2 expression in MeCP2-overexpressing mice (Na etal.,2012) andcerebellarcultures (Dastidaret al., 2012) could readily be used to test the proposed model. Given that Na et al. (2012) did not find a statistically significant increase in MeCP2 expression in cerebellar tissue, in which Dastidar et al. (2012) found an apoptotic phenotype, neuronal viability and synaptic activity in cerebella as well as hippocampi of these mice should also be examined to confirm the link between cell culture and in vivo effects of MeCP2 overexpression. Furthermore, given that FoxG1 overexpression and application of HDAC inhibitors rescued cellular phenotypes in vitro, these manipulations should be applied in vivo to MeCP2-overexpressing mice to determine whether the behavioral and cellular phenotypes are rescued. Such a rescue would further support a causal link between the cellular and behavioral deficits seen in MeCP2-overexpressing mice, illuminating promising avenues for therapeutic interventions in MECP2 DS.
Much research has been devoted to understanding and characterizing the effects of decreased expression and loss of function of MeCP2, particularly as it relates to RTT. The studies by Na et al. (2012) and Dastidar et al. (2012) introduce new perspectives on MeCP2 function and provide necessary models for MECP2 DS research. As the symptoms of MeCP2-related disorders indicate, understanding disease models and mechanisms associated with MeCP2 overexpression has wider implications beyond the cell for circuit-level and behavioral functions. These two studies represent important new steps toward understanding and eventually curing MeCP2-associated diseases. 
